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PENENTUAN MITRAGININA SEBAGAI SUBSTRAT, PENGARUH, ATAU 
PERENCAT P-GLIKOPROTEIN DAN RAMALAN RISIKO INTERAKSI 
DRUG-HERBA 
 
ABSTRAK 
P-Glikoprotein (P-gp) adalah protein pengangkut yang banyak terdapat di 
dalam tisu usus dan berfungsi dengan merembes keluar pelbagai substrat dari sel. 
Perubahan terhadap aktiviti, serta gen dan protein P-gp yang disebabkan oleh ubat-
ubatan atau sebatian herba akan menjejaskan bioketersediaan ubat yang dimakan dan 
berpotensi untuk meyebabkan interaksi di antara ubat dan ubat atau ubat dan herba. 
Mitragyna speciosa Korth atau Ketum digunakan secara tradisional untuk pelbagai 
penyakit tetapi disebabkan oleh kesan euforia, tumbuhan ini sering disalahgunakan 
oleh penduduk tempatan. Walaupun Ketum adalah bahan terkawal di negara-negara 
Asia, termasuk Malaysia, namun penggunaannya tidak dikawal selia dengan ketat di 
negara lain. Mitragynine adalah satu komponen bioaktif utama dalam ekstrak mentah 
Ketum dan keselamatan alkaloid ini dalam menyebabkan interaksi ubat dan herba 
melalui P-gp masih tidak disiasat sepenuhnya. Oleh itu objektif utama kami adalah 
untuk menentukan sama ada mitragynine adalah substrat P-gp atau mempunyai 
potensi untuk merencat atau meningkatkan aktiviti pengangkutan serta ekspresi P-gp 
di dalam sel kultur Caco-2. Satu kaedah penyaringan in silico, bagi meramal bentuk 
pengikatan mitragynine kepada P-gp telah dijalankan dengan menggunakan 
Autodock 4.2 dan seterusnya disahkan dengan menggunakan kaedah in vitro asai 
pengangkutan dwiarah. Pengoptimuman asai pengangkutan dwiarah telah dijalankan 
dan semua kompaun dianalisis menggunakan pengesan HPLC/UV dengan teknik 
elusi isokratik. Kesan mitragynine kepada ungkapan mRNA dan protein P-gp telah 
  
 
xxi 
 
dijalankan menggunakan optimisasi RT-qPCR, analisis Western blot serta 
immunofluorescence. Mitragynine tidak bertindak sebagai substrat P-gp berdasarkan 
kedua-dua simulasi dok molekul dan asai pengangkutan dwiarah. Walau 
bagaimanapun, mitragynine membentuk ikatan hidrogen dan interaksi hidrofobik 
dengan P-gp dan didapati menghalang aktiviti pengangkutan oleh P-gp dengan 
penurunan sebanyak 30% dibandingkan dengan kontrol. Mitragynine didapati 
merencatkan ungkapan mRNA serta protein P-gp. Pada kepekatan tertinggi, iaitu 10 
µM, perencatan ungkapan mRNA dan protein adalah sebanyak 35% dan 40% dan 
adalah selaras dengan penurunan dalam aktiviti pengangkutan digoxin melalui P-gp. 
Oleh itu, mitragynine adalah merupakan perencat P-gp secara in vitro. Rifampicin 
didapati mengaruh ekspresi protein P-gp setelah dinilai menggunakan kedua-dua 
analisis Western blot dan imunositokimia. Manakala, quinidine telah didapati 
merencat P-gp pada tahap transkripsi dan juga aktiviti pengangkutan P-gp. 
 
  
 
xxii 
 
DETERMINATION OF MITRAGYNINE AS A SUBSTRATE, INDUCER, OR 
INHIBITOR OF P-GLYCOPROTEIN DRUG TRANSPORTER, AND 
PREDICTION OF DRUG-HERB INTERACTION RISKS 
 
ABSTRACT 
P-glycoprotein (P-gp) is a multidrug transporter, mainly expressed in the 
intestinal tissue as a secretory efflux protein. Changes in the activity, gene and 
protein expression of P-gp caused by drugs or herbal compounds will affect oral drug 
bioavailability and may potentially lead to drug-drug or drug-herb interactions. 
Mitragyna speciosa Korth or Ketum is traditionally used for various ailments but due 
to its euphoric effects, this plant is often misused by the local population. Although 
Ketum is a controlled substance in most Asian countries, including Malaysia, its use 
is not strictly regulated in other parts of the world. Mitragynine is a major bioactive 
component in the crude extract of the plant and the safety of this alkaloid causing 
adverse drug interaction via P-gp has not been fully investigated. Therefore our main 
objective is to determine if mitragynine is a substrate of P-gp or has the potential to 
inhibit or induce the P-gp transport activity and expression in Caco-2 cells. An in 
silico computational method to predict the binding conformation of mitragynine to 
the substrate binding site as well as the nucleotide binding domain (NBD) of the P-
gp was carried out using Autodock 4.2 and further validated using in vitro 
bidirectional transport assay. Optimization of the bidirectional transport assay was 
carried out and both mitragynine and digoxin were analyzed using HPLC/UV 
detector with isocratic elution. The effects of mitragynine on mRNA and protein 
expression of P-gp were carried out using an optimized RT-qPCR, Western blot 
analysis and immunofluorescence. Mitragynine is unlikely a P-gp substrate based on 
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both the molecular docking simulation and bidirectional transport assay. However, it 
appears to form hydrogen bonds and hydrophobic interactions with P-gp and was 
found to inhibit the P-gp transport activity by 30% reduction when compared with 
control. Mitragynine was found to inhibit mRNA and protein expression of P-gp. For 
the highest concentration of 10 µM, inhibition of mRNA and protein were 
approximately 35% and 40% that of the control respectively and were consistent 
with the decrease in the transport activity of digoxin via P-gp. Thus, mitragynine is a 
significant in vitro P-gp inhibitor. Rifampicin was only found to significantly induce 
the protein expression evaluated using both Western blot analysis and 
immunocytochemistry. Meanwhile, quinidine was found to significantly inhibit the 
P-gp at the transcriptional level as well as its transport activity.   
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
Herbal medicine is used by herbalists and indigenous communities to prevent 
and treat various diseases over years. According to the definition by the World 
Health Organization (WHO), herbal medicines include herbs, herbal materials, 
herbal preparations, and finished herbal products that contain parts of plants, other 
plant materials, or combinations as active ingredients (Nworu et al. 2015). There are 
more than 35,000 species of plants worldwide which are known and used for 
medicinal purposes and about 250-500 species of plants that are commonly used in 
Asian and other countries (Chen et al. 2011). Herbal medicine is part of 
complementary and alternative medicine (CAM) where it comprises a diverse 
medical and health care systems, therapies, and products that are not presently 
considered to be part of conventional medicine (Barnes et al. 2004, 
Poonthananiwatkul et al. 2015). The usage of complementary and alternative 
medicine (CAM) has been increased in developing countries including Malaysia, and 
recently, the usage of CAM has also expanded to developed countries (Aziz and Tey 
2009). 
The 2012 National Health Interview Survey of the United States reported 
that, 38.3% of adults and 11.8% of children used herbal medicine and supplements 
which resulted in total expenditure of $30.2 billion (Black et al. 2015, Clarke et al. 
2015). In addition, other studies showed that an approximately 25% of adults in 
developed countries and more that 80% of the population in most developing 
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countries including Malaysia are using herbal medicine either for treatment of 
disease or as a supplement (Chen et al. 2011, Jayaray 2010, Mukherjee et al. 2011). 
From a survey conducted in Malaysia, about 63.9% Malaysian population are 
practicing and using herbal medicine and supplements. From 2000 to 2005, the 
annual sales for traditional medicines in Malaysia has increased from US$ 385 
million (RM 1 billion) to US$ 1.29 billion (RM 4.5 billion) (Aziz and Tey 2009).  
The number of herbal medicine and/or natural products users are increasing 
worldwide, partly due to the increasing preference for natural therapies and/or 
preventive medicine (Silvanathan and Low 2015). Rising concerns about the 
undesirable side effects of conventional medicine and the spreading belief that 
natural products are safer are known to be the contributing factors (Calixto 2000, 
Zhang et al. 2015). Other common reasons for herbal medicine consumption include 
the desire to improve physical and mental symptoms, and quality of life as well as to 
help deal with the disease and its unpleasant treatment (Poonthananiwatkul et al. 
2015). In Malaysia, the popularity of herbal medicine usage among the elderly was 
associated with its lower cost, a lower rate of side effects, more effective, more 
natural and better accessibility compared to conventional Western medicines (Mitha 
et al. 2013, Silvanathan and Low 2015). In addition, the usage of herbal medicine 
was also relatively high in middle-aged adults. Both patients and the public have 
been known to use herbal medicines to improve and maintain health, treatment or 
prevention of minor ailments as well as chronic diseases (Barnes 2003, Chang et al. 
2007, Mehta et al. 2007). Among Malaysian adults, being a woman, Malay, suffering 
from health problem, earning a high income, and having favourable opinions about 
herbal medicines were significant positive forecasters of use of herbal medicines 
(Aziz and Tey 2009). 
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However, with increasing number of herbal medicine usage, the number of 
adverse events which occurred after consumption of herbal product as well as herbal 
product abuse are also increasing. Ingestion of herbal products such as yohimbine (an 
alkaloid from Pausinystalia yohimbe), maca (Lepidium meyenii), horny goat weed 
(epimedium sp.), Mitragyna speciosa and Ginkgo biloba were reported to cause 
modification of the function of central nervous system which leads to changes in 
psychological behavioral and addiction (Corazza et al. 2014). Several herbal 
medicines, such as Ma-Huang (Ephedra sinica), kava (Piper methysticum), and 
chaparral leaf (Larrea divaricate), have been implicated as hepatotoxins where 
hepatotoxicity may be the most frequent adverse reaction to these herbal remedies 
when taken in excessive quantities. Other herbal plants such as Aspalathus linearis 
(red bush tea), Echinacea angustifolia and Valeriana officinalis may also cause 
hepatotoxicity as well as proved to have effects on coagulation and platelets function 
(Reddy et al. 2016, Wang et al. 2015).  
In Malaysia, the increasing use of herbal plant either for a herbal supplement, 
herbal medicine or herbal addiction and abuse by the community is of special 
concern because these herbal preparations are not strictly regulated by the Drug 
Control Authority (DCA) of Malaysia (Aziz and Tey 2009). The evaluation of the 
quality and safety of herbal medicines and supplements by the DCA of Malaysia 
before approval is only limited to control the content of specified adulterants and 
contaminants such as heavy metals and microorganisms (Aziz 2004, Bas and Oliu 
Castillo 2016). Thus, there is lack of information on the standard preparation 
procedure, general effects and its safety information for the herbal medicine to be 
considered safe for consumption. In addition, the main concern regarding the use of 
herbal medicine and supplements is the potential for dangerous adverse effects and 
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drug-herb interactions, especially when the herbal products were taken 
simultaneously with conventional medicine (Silvanathan and Low 2015). Hence, it is 
important to further investigate the safety, quality and therapeutic efficacy of herbal 
medicine as well as herbal plant derived compound.  
1.2 Drug interactions 
Drug-drug interaction (DDI) is defined as a pharmacological or clinical 
response to the administration of two or more drugs that is different from the 
response they initiate when individually administered (Rodrigues et al. 2015). Drug 
interactions occur when either pharmacokinetics or pharmacodynamics or both of 
one drug are altered by the co-administration of another drug. Changes in the 
pharmacokinetics and pharmacodynamics of one drug will affect the effectiveness of 
another either by causing treatment failure or toxicity (Chen and Raymond 2006). 
Drug interactions usually occur when one of the drug or xenobiotics having 
properties to interact with the mechanism of action, metabolism or transportation of 
the other drug. The effect may mimic, magnify or oppose the effect of drugs and 
usually produce adverse effects (Fugh-Berman 2000). These adverse reactions 
caused by the concomitant use of drugs or other xenobiotics can potentially lead to 
severe, and perhaps even life-threatening, adverse reactions. The severity of the 
adverse reaction can range from theoretical to clinically significant, including 
prolonged morbidity and even death (Chen et al. 2011, Manzi and Shannon 2005).  
In addition, many medicinal herbs and pharmaceutical drugs are therapeutic 
at one dose and toxic at another especially for drugs with narrow therapeutic indices 
such as digoxin and warfarin (Chen et al. 2011). Alteration in the pharmacology of 
those drugs leads to changes in the concentration of the drugs at the site of action 
producing side effects. Drug interactions are the most common causes for medication 
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error in a developed country, with a prevalence of 20-40% which mostly occurred in 
elderly due to polytherapy (Palleria et al. 2013).  Most of the drug interactions are 
potentiated by the concurrent use of herbals medicine and prescription drugs as 
identified by case reports and clinical studies worldwide (Chen et al. 2011). An 
example of DDIs is by co-administration of quinidine, dronedarone or verapamil 
with edoxaban and it has been found to increase the concentration of the edoxaban 
and lead to bleeding potential (Mendell et al. 2013).  In addition, administration of 
warfarin together with some known herbs such as cranberry, soya, St John’s wort, 
and danshen had been found to alter the concentration of warfarin and leading to 
drug-herb interactions (Ge et al. 2014). Generally, the mechanism for drug 
interactions is divided into two types, namely pharmacodynamics and 
pharmacokinetics mechanism of drug interactions as shown in Figure 1.1. 
1.3 Pharmacodynamic mechanism of drug interactions 
Pharmacodynamics is the study of how drugs have effects on the body 
(Maxwell 2016, Meibohm and Derendorf 1997). Pharmacodynamics interactions are 
the result of the effects of combined treatment at the site of action which altered 
pharmacological actions at standard plasma concentration (Kashuba and Bertino 
2005, Palleria et al. 2013). Pharmacodynamic interactions are more difficult to 
identify and measure than pharmacokinetic interactions since they result in a 
modification of the pharmacological action of a drug without any change in the 
plasma concentration (Spina et al. 2016). Pharmacodynamic interactions are divided 
into three subgroups based on the mechanism either by direct effect at receptor 
function, interference with a biological or physiological control process, or additive 
or opposed pharmacological effect (Palleria et al. 2013). The effects of  
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Figure 1.1 Generalized mechanistic insight into drug interactions where it can be 
divided into two based on the mechanism, pharmacokinetics drug 
interactions and pharmacodynamics drug interactions. Adapted from 
Underestimating the Toxicological Challenges Associated with the 
Use of Herbal Medicinal Products in Developing Countries, page 6 
(Neergheen-Bhujun 2013).  
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pharmacodynamics type of drug interactions can either be synergistic where the 
combined effects are greater than expected from the sum of individual effects, 
additive where the effects are equal to the sum of the effects of the individual drugs, 
or antagonistic where the combined effects are less than additive (Spina and Italiano 
2015). The ability of diverse xenobiotics to interact with different receptor sites and 
alter the physiological environment can also partly explain pharmacodynamic 
interactions.  
1.4 Pharmacokinetic mechanism of drug interactions 
Pharmacokinetics interaction is defined as changes in the absorption, 
distribution, metabolism or excretion of a drug and/or its metabolite(s) after the co-
administration of another drug (Spina et al. 2016). These interactions affect the way 
xenobiotics or drugs are absorbed, distributed, metabolized and excreted, resulting in 
altered plasma drug concentration (Ge et al. 2014, Spina et al. 2016). Over the past 
decade, drug metabolism was known as a major contributor in drug interactions. 
However, other than metabolism, drug absorption, distribution, and excretion are 
also shown to have important influences on pharmacokinetics, bioavailability, and 
consequently therapeutic efficacy of drugs (Faber et al. 2003, Meyer et al. 2015, 
Muller and Fromm 2011). Both in vitro and in vivo studies have indicated that 
hepatic or intestinal drug-metabolizing enzymes and drug transporters both equally 
contribute to the pharmacokinetic interactions (Zhou et al. 2003).  
1.4.1 Drug absorption and distribution 
 Drug absorption refers to the movement of the drug from its site of 
administration (either via gastrointestinal tract or skin) into the blood circulation. 
Once a drug has gained access to the blood circulation, it will be distributed to other 
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tissues for any effects to be produced. Drugs absorption can occur via passive 
diffusion, facilitated diffusion or active transport by protein transporters into the 
blood circulation before distribution takes place (Artursson et al. 2012, Chillistone 
and Hardman 2014). For drugs with oral route of administration, absorption occurs in 
the lower part of the gastrointestinal tract (jejunum and ileum of the small intestine 
and large intestine) due to the larger surface area of the intestine (Bergström et al. 
2014). The absorption process occurs via the enterocytes lining the intestinal tract. 
Enterocytes are polarized simple columnar epithelial cells with microvilli on the 
apical surface of the cells and joined together by tight junctions (Snoeck et al. 2005).  
The most common mechanisms of interaction occurring during absorption are 
an alteration in the active and passive intestinal transport, alteration in the intestinal 
cytochrome P450 isozyme activity, alteration in the intestinal P-glycoprotein (P-gp) 
activity, and alteration of gastric pH, gastric emptying, intestinal motility, and 
intestinal blood flow (Kashuba and Bertino 2005). In addition, absorption across the 
intestinal membrane is also affected by other transporters on both luminal and 
basolateral membrane. These transporters can be either influx or efflux type of 
transporter (Chillistone and Hardman 2014). Other than P-glycoprotein, other drug 
transporters such as organic anion transporter (OAT), organic cation transporter 
(OCT) and solute carrier (SLC) transporter which are also abundantly expressed in 
the drug’s absorption site are responsible for maintaining balanced absorption in the 
intestine (Tsuji 2002).  
1.4.2 Drug metabolism 
Drug metabolism and drug excretion represent the detoxification processes 
that protect the human body from xenobiotics and their toxic metabolites (Leslie et 
al. 2005). Generally, drug metabolism or biotransformation is a chemical alteration 
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of the drug in the body (Peng and Zhong 2015). Liver is the primary site for drug 
metabolism and this process can be divided into two phases, which are phase I 
metabolism and phase II metabolism (Konstandi et al. 2014, Nowak et al. 2014). 
Hepatic detoxification is generally initiated by the uptake of xenobiotics into liver 
hepatocytes, by uptake transporter followed by phase I metabolism such as reduction, 
oxidation, and hydrolysis. Subsequently, phase II metabolism by conjugation 
processes such as glutathione conjugation, glucuronidation, and sulfation are 
performed before proceeding with excretions of xenobiotics and/or their metabolites 
to the bile or through renal excretion (Song et al. 2013).  
In drug interactions, potential mechanisms involving metabolism are the 
genetic polymorphism, inhibition, and induction of enzyme activity (Kashuba and 
Bertino 2005). Nonrandom genetic modification generates polymorphisms which 
occurred in at least 1% of a population and give rise to distinct subgroups that differ 
in their ability to metabolized xenobiotics (Daly et al. 1998).  For the inhibition of 
enzyme activity, there are several mechanisms of inhibition exist such as reversible 
and irreversible inhibition where reversible is the most common type of enzyme 
inhibition. Reversible inhibition do not permanently disable the enzyme activity and 
it occurs when weak bonds were quickly formed between compounds and CYP P450 
isozyme (Kashuba and Bertino 2005). This reversible inhibition can occur both 
competitively and noncompetitively. In addition, there is also reversible inhibition 
due to the oxidation of inhibitor which forms a slowly reversible reactions (Thummel 
and Wilkinson 1998). The formation of CYP-mediated reactive metabolite caused 
irreversible inhibition and this metabolite can covalently and irreversibly bind to the 
catalytic site residue which permanently inactivate the enzyme (Ho et al. 2015). For 
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induction of enzyme activity, it generally happens with an increase in P450 synthesis 
either by mRNA stabilization or receptor-mediated transcriptional activation.   
1.4.3 Drug elimination 
 Kidneys play an important role in drug excretion. Liver and kidney 
transporters such as solute carrier (SLC) transporter family and ATP-binding cassette 
(ABC) transporter family are known to play an important role in excretion and 
elimination of drugs and other foreign substances from the body (Le Vee et al. 2015). 
Generally, elimination can occur via tubular secretion, glomerular filtration, or a 
combination of both pathways. Recently, the role of these transporters in the 
excretion of drugs have drawn major attention because of their involvement in drug 
interactions (Moss et al. 2014). SLC transporter family can be subdivided into 
cationic transporters, anionic transporters, and other transporters. These SLC 
transporters family are expressed in both apical and basolateral membrane of the 
proximal tubule cells and control the entry of xenobiotics into the epithelial cells 
(Morrissey et al. 2013). Meanwhile, ATP-binding cassette (ABC) transporter help to 
eliminate and excrete xenobiotics and endogenous compounds across the proximal 
tubule cells in kidney, the apical membrane of hepatocytes, capillary endothelial cells 
at the blood-brain barrier as well as the brush border membrane of enterocytes 
(Giacomini et al. 2010, van Montfoort et al. 2003).   
 There are five potential mechanisms of drug interactions affecting excretion 
at the site of renal elimination (Bonate et al. 1998). The three most common 
mechanisms are glomerular filtration, tubular secretion, and tubular reabsorption. 
Changes in renal blood flow, cardiac output, and extend of protein binding will affect 
rates of glomerular filtration which disturb the normal excretion process (Kashuba 
and Bertino 2005). However, the most common renal drug interactions occur at the 
  
 
11 
 
transport site of tubular secretion. Many organic anions and cationic drugs and 
metabolites compete with each other for secretion as they are sharing the same 
proximal tubular active transport system. In addition, inhibition of renal P-gp which 
has been identified in the apical membrane of the proximal tubule leads to an 
increase in plasma drug concentrations and potentially contribute to significant drug 
interactions. In tubular reabsorption, changes in the urinary pH can alter the 
reabsorption process but these interactions are not known to be clinically significant. 
1.5 Membrane transporter 
 As discussed earlier, transporters and drug metabolizing enzymes are two 
major components, playing an important role in pharmacokinetics drug interactions 
(Wu et al. 2016). While many researches have been focused on the role of drug 
metabolizing enzymes in drug interactions, less emphasis has been placed on the 
importance of transporter in drug interactions. Transporters mostly involve in the 
absorption, distribution and elimination of xenobiotics either into or outside of the 
cells, whereas drug metabolizing enzymes are mostly involved in the metabolism 
process (Scherrmann 2009). The major physiological functions of transporters are to 
facilitate the transfer of nutrients or endogenous substrate across the cell membrane, 
such as endogenous metabolites and signaling molecules. There are two main 
transporter superfamilies, namely SLC and ABC transporters and both are involved 
in transporter-mediated drug interactions (Giacomini et al. 2010). SLC transporters 
comprise of facilitated and ion-coupled transporters, including organic cation 
transporters (OCTs), organic anion transporters (OATs) and organic anion-
transporting polypeptides (OATPs), where most of the SLC transporters mediate 
uptake of substrates into the cells (Koepsell 2013, Wessler et al. 2013). On the other  
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hand, ABC transporters, including P-glycoprotein (P-gp or MDR1), breast cancer 
resistance protein (BCRP or ABCG2), and multi-drug resistance associated proteins 
(MRPs), are considered to be responsible for efflux of xenobiotics where they rely on 
ATP to actively pump their substrate across cell membranes (Leslie et al. 2005). 
These specific uptake and efflux transporters are extensively expressed in the apical 
and luminal membrane of epithelia of many organs as shown in Figure 1.2 
(Giacomini et al. 2010, Sai 2005). Their expression in cells of all of these major 
barriers such as intestine, blood-brain barrier as well as in metabolic organs such as 
liver (hepatocytes) and kidney (kidneys proximal tubules) also explains their 
influence on the pharmacology properties of drugs and drugs candidates (Estudante 
et al. 2013, Montanari and Ecker 2015). Among all the protein transporters, ABC 
transporters especially P-gp has drawn major attention for its great influence on drug 
resistance and drug interactions problem (Hennessy and Spiers 2007, Li et al. 2014).  
1.6 ABC transporter superfamily 
The ATP-binding cassette (ABC) transporters form a large superfamily of 
membrane proteins which are responsible for various functions, including the active 
transportation of ions and peptides, excretion of harmful compounds, and cell 
signaling (Leslie et al. 2005). There are more than 100 membrane 
transporters/channels in the ABC transporter superfamily and they are universally 
expressed in all living organisms ranging from prokaryotes to mammals (Hennessy 
and Spiers 2007, Montanari and Ecker 2015). In humans, 49 ABC transporters have  
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Figure 1.2 Various distribution of protein transporter in the membrane of cells in 
the a) intestine, b) liver, c) kidney, and d) brain are shown. Arrows 
represent the direction of substrate transport for each transporter. 
Orange circles: key drug transporters mentioned in both US FDA 
draft guidance and EMA guideline on DDIs (Giacomini et al. 2010, 
Maeda and Sugiyama 2013).  
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been identified, and organized into 7 subfamilies: ABCA (12 members; previously 
ABC1), ABCB (11 members; previously MDR/TAP), ABCC (13 members; 
previously MRP/CFTR), ABCD (4 members; previously ALD), ABCE (1 member; 
previously OABP), ABCF (3 members; previously GCN20) and ABCG (5 members; 
previously White) (Table 1.1) (Dean and Allikmets 2001, Dean et al. 2001, Vasiliou 
et al. 2009). These ABC transporters consist of several core domains (transmembrane 
domains and intracellular nucleotide binding domains) depending on different 
subfamilies. The nucleotide binding domains (NBDs) are usually well conserved 
across subfamilies while transmembrane domains (TMDs) are less conserved and 
possibly account for substrate specificity of the different transporters. In addition, 
these TMDs form the translocation chamber across the transporter which explained 
the ability for their substrate to be transported (Tarling et al. 2013).  
Generally, the TMD of ABC transporters consists of few membrane spanning 
segments (α-helices) separates by hydrophilic loops and intracellular NBD (Kast et 
al. 1995, Loo and Clarke 1995). In each NBDs, two sequence motifs known as 
Walker A and Walker B which located 100-200 amino acids apart, are conserved 
among all ABC transporter superfamily members, as well as numerous other ATP-
binding proteins (Walker et al. 1982). The lysine residue in the Walker A motif is 
involved in the H-bonding with the ATP while the aspartic acid residue in the 
Walker B motif interacts with Mg2+ (Hung et al. 1998, Sharom et al. 1999). In 
addition, another highly conserved amino acid sequence, ABC signature motif or C 
motif (ALSGGQ) which located between the Walker A and B motifs, as well as the 
D,H, Q, and A loops were known to have implication in the recognition, binding, and 
hydrolysis of ATP. Several of these motifs shown to interact with the adenine ring of 
ATP and appear to form part of the ATP-binding site (Loo et al. 2002). 
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Table 1.1 Human ABC transporter genes, and their functions (Dean et al. 2001). 
Gene 
Chromosome 
location 
Exons  AA 
Accession 
number 
Function 
ABCA1 9q31.1 36 2261 NM005502 
Cholesterol efflux onto 
HDL 
ABCA2 9q34 27 2436 NM001606  Drug resistance 
ABCA3 16p13.3 26 1704 NM001089  Multidrug resistance 
ABCA4 1p22 38 2273 NM000350 
N-retinylidene-
phosphatidylethanolamine 
(PE) efflux 
ABCA5 17q24.3 31 1642 NM018672 
Urinary diagnostic marker 
for prostatic 
intraepithelial neoplasia 
(PIN) 
ABCA6 17q24.3 35 1617 NM080284 Multidrug resistance 
ABCA7 19p13.3 31 2146 NM019112 Cholesterol efflux 
ABCA8 17q24 31 1581 NM007168 
Transports certain 
lipophilic drugs 
ABCA9 17q24.2 31 1624 NM080283 
Might play a role in 
monocyte 
differentiation and 
macrophage lipid 
homeostasis 
ABCA10 17q24 27 1543 NM080282 
Cholesterol-responsive 
gene 
ABCA12 2q34 37 2595 NM173076 
Has implications for 
prenatal diagnosis 
ABCA13 7p12.3 36 5058 NM152701 
Inherited disorder 
affecting the pancreas 
ABCB1 7q21.1 20 1280 NM000927  Multidrug resistance 
ABCB2 6p21.3 11 808 NM000593  Peptide transport 
ABCB3 6p21.3 11 703 NM000544 Peptide transport 
ABCB4 7q21.1 25 1279 NM000443  
Phosphatidylcholine (PC) 
transport 
ABCB5 7p15.3 17 812 NM178559  Melanogenesis 
ABCB6 2q36 19 842 NM005689  Iron transport 
ABCB7 Xq12-q13 14 753 NM004299  Fe/S cluster transport 
ABCB8 7q36 15 718 NM007188 
Intracellular peptide 
trafficking across 
Membranes 
ABCB9 12q24 12 766 NM019625  Located in lysosomes 
ABCB10 1q42.13 13 738 
NM012089  
 
Export of peptides derived 
from proteolysis of inner-
membrane proteins 
ABCB1 2q24 26 1321 NM003742  Bile salt transport 
ABCC1 16p13.1 31 1531 NM004996  Drug resistance 
ABCC2 10q24 26 1545 NM000392  Organic anion efflux 
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Table 1.1 Continued 
Gene 
Chromosome 
location 
Exons  AA 
Accession 
number 
Function 
ABCC3 17q22 19 1527 NM003786  Drug resistance 
ABCC4 13q32 19 1325 NM005845  Nucleoside transport 
ABCC5 3q27 25 1437 NM005688  Nucleoside transport 
ABCC6 16p13.1 28 1503 NM001171  
Expressed primarily in 
liver and kidney 
ABCC7 7q31.2 23 1480 NM000492  
Chloride ion channel 
(same as CFTR gene 
in cystic fibrosis) 
ABCC8 11p15.1 30 1581 NM000352  Sulfonylurea receptor 
ABCC9 12p12.1 32 1549 NM005691 
Encodes the regulatory 
SUR2A subunit of 
the cardiac Kþ(ATP) 
channel 
ABCC10 6p21.1 19 1464 NM033450  Multidrug resistance 
ABCC11 16q12.1 25 1382 NM033151  
Drug resistance in breast 
cancer 
ABCC12 16q12.1 25 1359 NM033226  Multidrug resistance 
ABCC13 21q11.2 6 325 NM00387  
Encodes a polypeptide of 
unknown 
Function 
ABCD1 Xq28 9 745 NM000033  
Very-long-chain fatty acid 
(VLCFA) 
Transport 
ABCD2 12q11-q12 10 740 NM005164  
Major modifier locus for 
clinical diversity 
in X-linked ALD (X-
ALD) 
ABCD3 1p22-p21 16 659 NM002858  
Involved in import of fatty 
acids and/or 
fatty acyl-coenzyme As 
into the 
peroxisome 
ABCD4 14q24 19 606 NM005050  
May modify the ALD 
phenotype 
ABCE1 4q31 14 599 NM002940  
Oligoadenylate-binding 
protein 
ABCF1 6p21.33 19 845 
NM001025
091  
Susceptibility to 
autoimmune pancreatitis 
ABCF2 7q36 14 634 
NM005692  
 
Tumour suppression at 
metastatic sites and 
in endocrine pathway for 
breast cancer/ 
drug resistance 
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Table 1.1 Continued 
Gene 
Chromosome 
location 
Exons  AA 
Accession 
number 
Function 
ABCF3 3q27.1 21 709 
NM018358  
 
Also present in 
promastigotes (one of five 
forms in the life cycle of 
trypanosomes) 
ABCG1 21q22.3 13 678 NM004915  Cholesterol transport 
ABCG2 4q22 16 655 NM004827 
Toxicant efflux, drug 
resistance 
ABCG4 11q23.3 15 646 NM022169 
Found in macrophage, eye, 
brain and spleen 
ABCG5 2p21 11 651 NM022436 Sterol transport 
ABCG8 2p21 10 673 NM022437 Sterol transport 
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1.7 P-glycoprotein (P-gp) 
1.7.1 Background and structure of P-gp 
P-glycoprotein (P-gp) is one of the drug transporters that play an important 
role in the pharmacokinetics of drugs or xenobiotics. It is a 170 kDa (~170-180 kDa) 
polypeptide consisting of approximately 1280 amino acids (Chen et al. 1986, Miyata 
et al. 2016). P-gp is a multidrug transporter and one of the members of the ABC 
(ATP-binding cassette) superfamily encoded by the MDR1 gene in human which is 
now known as ABCB1 (Hennessy and Spiers 2007). Since P-gp is one of ABC 
transporter, the basic units of P-gp consists of two units of TMDs and two units of 
NBDs as depicted in Figure 1.3. In addition, it appears that P-gp is generated by a 
gene duplication event, fusing two related half molecules (van Veen et al. 2000). 
Each half molecules consists of one unit of TMD and one unit of NBD (Miyata et al. 
2016). Generally, the two homologous halfs of the protein were connected by a 
central sequence known as the “linker” region. The two half share 43% sequence 
identity and 78% similarity (Grandjean-Forestier et al. 2009). 
The TMD unit was made up of six transmembrane segments where each 
segment is connected by extracellular or cytosolic loops as shown in Figure 1.3b. 
The last cytosolic loop was then, followed by a large cytosolic domain containing an 
ATP-binding site or NBD where the first half is NBD1 and the second half is NBD2 
(Dean et al. 2001, Silva et al. 2015). Furthermore, the secondary structure of P-gp 
shows that it consists of approximately 32-43% α-helix, 16-26% β-sheet, 15-29% β-
turn and 13-26% unordered structure (Dong et al. 1998, Sonveaux et al. 1996).  
In P-gp, two TMDs units constitute the drug transport pore while, the NBDs 
bind and hydrolyze ATP to provide energy for the movement of its substrates across 
membranes (Wessler et al. 2013). For efficient ATP hydrolysis, there is evidence that 
  
 
19 
 
the two NBDs have to interact by forming a sandwich dimer so that the LSGGQ 
motif of one NBD comes into contact with the loop of the other NBD to form the 
nucleotide-binding pocket (Leslie et al. 2005). The linker region also plays a role in 
P-gp function by creating flexible secondary structure. This flexibility is sufficient 
for the coordinate functioning of both halfs of P-gp, which are likely required for the 
proper interaction of the two ATP-binding sites (Grandjean-Forestier et al. 2009). 
In normal cells expressing P-gp, this protein is synthesized in the 
endoplasmic reticulum as a core glycosylated intermediate with a molecular weight 
of 150 kDa before subsequently modified in the Golgi apparatus prior to export to 
the surface of the cell (Grandjean-Forestier et al. 2009). P-gp protects the cells from 
xenobiotics and toxins by pumping them out from the cells. The efflux of the drug 
helps in preventing it from reaching the systemic circulation (Vaalburg et al. 2005). 
P-gp is mainly expressed at the apical (luminal) side of the epithelial cells of the 
intestine (enterocytes), in the brain capillary endothelial cell of the blood brain 
barriers, renal proximal tubular cells, hepatocytes, blood-testis barrier in testis as 
well as in placental fetal-maternal barrier (Figure 1.4). 
Generally, P-gp works in two steps where the first is a catalytic cycle of ATP 
hydrolysis, while second is the movement of the substrate from the cytoplasmic side 
to the extracellular side of the membrane (Grandjean-Forestier et al. 2009). In normal 
state, the P-gp pore opens towards the cytoplasm of the cells with both NBDs and 
TMDs open inward as shown in Figure 1.5. The substrate from the cytoplasm will 
bind to the substrate binding-site located within the cytoplasmic membrane leaflet 
(Higgins and Gottesman 1992). Then, low-affinity binding of ATP to both 
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Figure 1.3 Basic units of P-gp which consist of two related half molecules (each 
molecules consists of one unit of TMD and one unit of NBD). a) 
Transport cycle for substrate efflux pumped by P-glycoprotein 
(substrates are colored red and ATP is magenta) b) Topological model 
of P-gp, showing the two homologous halfs, each with one 
transmembrane domain (TMD), containing six highly hydrophobic 
transmembrane α-helices, and one nucleotide binding domain (NBD) 
located on the cytoplasmic side of the membrane (Chen et al. 2012). 
 
 
 
a) 
b) 
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Figure 1.4 Localization of P-gp in various organs of human (Borst and Schinkel 
2013). 
 
 
 
 
 
 
 
 
  
 
22 
 
NBDs will induce the formation of a putative nucleotide sandwich dimer which drive 
the transportation process (Hennessy and Spiers 2007). At this stage, both the TMDs 
and NBDs are closed inward and catalysis of ATP into ADP and phosphate occurs. 
Subsequently, the TMDs open outward allowing the substrate to be transported to the 
extracellular space (Wu et al. 2016). Finally, P-gp transforms back to its normal 
conformation releasing the ADP and phosphate.  
1.7.2 Substrates of P-gp  
 Due to its extreme broad substrate specificity (poly-specificity or 
promiscuity) in P-gp, it can actively transport a plethora of substrates compounds 
with varying size and structure out of the cells (Montanari and Ecker 2015, Pan et al. 
2016). P-gp is unique in its ability to recognize and transport its substrates that differ 
considerably in chemical structure and pharmacological action, including many 
clinically important agents. In earlier studies, P-gp is known to plays a role in 
multiple drug resistance especially in cancer therapy (Januchowski et al. 2016). 
Many of these anti-cancer drugs that are important in managing the cancer patients 
such as doxorubicin, and daunorubicin were known to be a P-gp substrate (Al-Saraf 
et al. 2016). Other than these two anthracyclines, P-gp can also transport other anti-
cancer drugs such as vinblastine, vincristine, actinomycin D, paclitaxel, teniposide, 
and etoposide (Hennessy and Spiers 2007).  
 Other therapeutic drugs such as HIV protease inhibitors (maraviroc), 
gastrointestinal agents (loperamide, ondansetron) as well as rheumatologic or 
immunosuppressant agents (cyclosporine, tacrolimus) were found to be transported 
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Figure 1.5 Mechanism for transportation of substrate via P-gp (Wu et al. 2016) 
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by P-gp (Alam et al. 2016, Mendes et al. 2009, Wagner et al. 2001). In addition, 
antimicrobial agents such as erythromycin, as well as anti-helminthic agent such as 
ivermectin, were also known to be a P-gp substrates (Griffin et al. 2005, Takano et 
al. 1998). Neurologic agents which are used in treating pain in post-herpetic 
neuralgia as well as for local analgesia such as lidocaine are also transported by P-gp 
(Funao et al. 2003, Wessler et al. 2013). Interestingly, there is rising concern on the 
roles of  P-glycoprotein in cardiovascular as these cardiac agents are found to interact 
with P-gp (Wessler et al. 2013). For example, antiarrhythmic agents such as digoxin 
and verapamil which are indicated for congestive cardiac failure and cardiac 
arrhythmia are known as P-gp substrates (Hansen et al. 1997, Römermann et al. 
2013, Tuncok et al. 1997). P-gp can also transports anticoagulant agents such as 
dabigatran, edoxaban and warfarin as well as antiplatelet agents such as clopidogrel 
and ticagrelor (Chen et al. 2016, Mendell et al. 2011, Wessler et al. 2013). In 
addition, statins such as lovastatin and atorvastatin have been found to be transported 
by P-gp and co-administration of any P-gp inhibitor will affects its bioavailability 
(Goard et al. 2010). P-gp can also transport talinolol, an antihypertensive agents used 
for treatment of hypertension and to manage cardiac arrhythmias (Eyal et al. 2009, 
Nguyen et al. 2014). Other than these therapeutic drugs, plant crude extract as well as 
its natural compound such as berberine which is an alkaloid extracted from Berberis 
vulgaris is also proved to be transported by P-gp (Gozalpour et al. 2014). 
1.7.3 Inhibitor and inducer of P-gp 
Some compounds and xenobiotics are found to interact with P-gp by causing 
inhibition or induction. For example, antimicrobial agents such as ketoconazole and 
erythromycin produce inhibitory effects on P-gp transport activity (Stappaerts et al. 
2013). Tariquidar, an anti-cancer agent which is known as P-gp substrate is also 
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found to act as P-gp inhibitor (Loo and Clarke 2014). Oral amiodarone and quinidine 
inhibit intestinal P-gp membrane efflux causing increased plasma concentration of P-
gp substrate (Fromm et al. 1999, Robinson et al. 1989). In addition, dronedarone, 
another antiarrhythmic agents, displays an even greater inhibition on the P-gp 
transport activity compared to amiodarone (Vallakati et al. 2013). Other than 
antiarrhythmic agents, calcium-channel blockers such as nicardipine, verapamil, 
nifedipine and diltiazem inhibit the P-gp mediated transportation of P-gp substrate 
(Cavet et al. 1996, Takara et al. 2002). Preliminary evidence suggests that warfarin, 
an oral anticoagulant may inhibit P-gp activity in liver cells. Other than these 
therapeutic drugs, other xenobiotics such as propiconazole which commonly used on 
fruits and vegetables as an agricultural fungicide was shown to inhibit the P-
glycoprotein transport activity (Mazur et al. 2015). P-gp was also found to be 
inhibited by spinosad, an oral flea insecticide and was suggested as the underlying 
cause of the drug interactions with ivermectin (Schrickx 2014). For instance, 
sinapine which is a small molecular alkaloid extracted from the seeds of cruciferous 
vegetable (traditional Chinese medicine) plays an important role in downregulation 
of P-gp expression in tumors (Guo et al. 2014). Another alkaloid compound from 
gum resin of Commiphora mukul (guggulsterone) also showed inhibition potential of 
cyclooxygenase-2 by downregulating the P-gp expression and was suggested to be 
used to reverse the imatinib-resistance problem (Xu et al. 2014). 
On the contrary, some of these conventional drugs as well as other 
xenobiotics also act to induce the P-gp activity and might also induce its expression. 
Rifampicin which is used for treatment of several types of bacterial infections 
especially tuberculosis and leprosy, upregulate as well as inducing P-gp transport 
activity. Digoxin which is also known as P-gp substrate, also act to induce both the  
